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Matrix metalloproteinase-14 (MMP-14) promotes vulnerable plaque morphology in mice, whereas tissue inhibitor of
metalloproteinases-3 (TIMP-3) overexpression is protective. MMP-14hi TIMP-3lo rabbit foam cells are more invasive and more
prone to apoptosis than MMP-14lo TIMP-3hi cells. We investigated the implications of these findings for human atherosclerosis.
In vitro generated macrophages and foam-cell macrophages, together with atherosclerotic plaques characterised as unstable
or stable, were examined for expression of MMP-14, TIMP-3, and inflammatory markers. Proinflammatory stimuli increased
MMP-14 and decreased TIMP-3 mRNA and protein expression in human macrophages. However, conversion to foam-cells with
oxidized LDL increased MMP-14 and decreased TIMP-3 protein, independently of inflammatory mediators and partly through
posttranscriptional mechanisms. Within atherosclerotic plaques, MMP-14 was prominent in foam-cells with either pro- or anti-
inflammatory macrophage markers, whereas TIMP-3 was present in less foamy macrophages and colocalised with CD206. MMP-
14 positive macrophages were more abundant whereas TIMP-3 positive macrophages were less abundant in plaques histologically
designated as rupture prone. We conclude that foam-cells characterised by highMMP-14 and low TIMP-3 expression are prevalent
in rupture-prone atherosclerotic plaques, independent of pro- or anti-inflammatory activation.Therefore reducingMMP-14 activity
and increasing that of TIMP-3 could be valid therapeutic approaches to reduce plaque rupture and myocardial infarction.
1. Introduction
Plaque rupture accounts for three quarters of myocardial
infarctions [1]. Weakening of the fibrous cap owing to net
degradation of extracellular matrix is believed to play an
important part in plaque rupture [2]. Foam-cell macrophages
(FCMs) are an abundant source of several matrixmetallopro-
teinases (MMPs) in human plaques [3, 4]. Protective effects of
certainMMPs on smoothmusclemigration and proliferation
have been identified from experimental studies but high
levels of MMP production, especially from FCMs, have been
implicated in plaque progression and rupture [2]. Attention
has focused recently onMMP-14, which is an activatedmem-
brane type MMP, and a tissue inhibitor of MMPs (TIMP-
3), which binds to the extracellular matrix. Given these
properties, MMP-14 and TIMP-3 are likely to play important
divergent roles in the regulation of macrophage pericellular
proteolysis. Adoptive transfer of leukocytes lacking MMP-14
into LDL-receptor null mice increased plaque collagen con-
tent, implying a harmful collagen-depleting role of MMP-14
in plaque stability [5]. Conversely, transgenic overexpression
of TIMP-3 in mouse macrophages reduced atherosclerosis
formation and improved markers of plaque stability [6].
A MMP-14hi TIMP-3lo subpopulation of rabbit FCMs was
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shown to have greater proteolytic capacity, ability to invade
through synthetic extracellular matrix (ECM), and greater
propensity to undergo apoptosis, all of which would be
expected to favour plaque rupture [7]. MMP-14hi TIMP-3lo
FCMs were identified in human atherosclerotic plaques
[7] but the mechanisms responsible for generating the
MMP-14hi TIMP-3lo FCMs and their relationship to plaque
vulnerability in man were not previously investigated.
Macrophages can express a spectrum of different acti-
vation states dependent on pro- and anti-inflammatory sig-
nals [8, 9], although the effects on MMP-14 and TIMP-3
expression are not fully documented. For example, activation
by Toll-like receptor agonists [10] and other inflamma-
tory cytokines acting through nuclear factor-𝜅B (NF-𝜅B)
upregulates several MMPs [11]. Such activated macrophages
have been associated with unstable plaque morphology,
whereas deactivated or alternatively activated macrophages
are associated with increased plaque stability in most [12–
14], although not all, studies [15]. Phenotypes resulting from
oxidised phospholipids [16] or by the action of haem at sites
of thrombosis and intraplaque haemorrhage have also been
recently distinguished [17–19].
To clarify the nature and role of MMP-14hi TIMP-3lo
FCMs we investigated their activation in vitro with pro- and
anti-inflammatory molecules. We then investigated whether
macrophage populations with opposing expression of MMP-
14 and TIMP-3 colocalise with markers of macrophage acti-
vation and correlatewith histologicalmarkers of vulnerability
to rupture in human carotid atherosclerotic plaques.
2. Materials and Methods
2.1. Carotid Artery Specimens. Carotid endarterectomy spec-
imens came from the AtheroExpress Biobank, the details
of which have been described in detail elsewhere [20–22].
Briefly, patient demographics including cardiovascular risk
factors, previous medication use, and presenting symptoms
were recorded. Atherosclerotic plaques were dissected by
a dedicated technician into 5𝜇m thick cross-sectional seg-
ments. Histological staining (haematoxylin and eosin (HE),
Picrosirius Red (PS)) were performed on the so-called culprit
lesion (segment with largest plaque area). The area occu-
pied by following parameters was scored semiquantitatively
as described previously [20–22]: atheroma core (HE, PS),
calcification, (HE), collagen (PS), smoothmuscle cells (𝛼SM-
ctin; M0851; Dako), and macrophages (CD68; M0814; Dako)
(Table 1). Smooth muscle cells and macrophages were also
scored quantitatively by using a microscope equipped with
a digital camera and using AnalySIS 3.2 software (Soft
Imaging System GmbH, Munster, Germany). The amount of
microvessels was quantified by using an anti-CD34 antibody;
details have been described previously [20–22]. As specified
in the AtheroExpress protocol, histological sections were
classified according to overall appearance into: “atheroma-
tous lesions” containing a large lipid core (>40% of plaque
area), high macrophage infiltration with low smooth muscle
cell and collagen content, “fibrous lesions” with a small
(<40%) or absent lipid core, low macrophage content and
high smooth muscle cell and collagen content, and “fibrous-
atheromatous lesions” as an intermediate between the two
other phenotypes. The inter- and intraobserver variability
for this classification has been described previously [23].
Adjacent sections were then taken for the histological anal-
yses reported here, which were performed and analysed by
2 additional operators who were blinded as to the lesion
classification.
2.2. Immunohistochemistry. Sections were dewaxed in Clear-
ene and rehydrated in absolute alcohol. After rinsing in
distilled water, slides were subjected to heat-induced antigen
retrieval by incubation in citrate buffer (10mM citric acid
in 1x PBS, pH 6.0) and microwaved for 10 minutes at full
power. Slides were allowed to cool for 30 minutes and
then washed with PBS (3 × 2 minutes). For brightfield or
fluorescence IHC, 50 𝜇L of 1% bovine serum albumin or
Image-iT FX Signal Enhancer (Invitrogen, Life Technolo-
gies, Paisley, UK), respectively, was placed on sections and
incubated at room temperature for 30 minutes. The solution
was then removed by tapping the slides and 50 𝜇L of the
applicable primary antibody (as detailed in Table 1) added
to the samples and incubated either overnight at 4∘C or
for 1 hour at room temperature. Sections were then washed
in PBS (3 × 2 minutes each) and incubated in the desired
secondary antibody as detailed in Table 1. For fluorescent
labelling, sections were incubated in the dark for 1 hour at
room temperature. Sections were then washed in PBS (3 × 2
minutes) and mounted with ProLong Gold antifade reagent
containing DAPI (Invitrogen, Life Technologies, Paisley, UK)
to identify the nuclei. A negative control where the primary
antibody was replaced with the relevant species IgG at
the same dilution was always included and the cells were
counted in 6 × 20 magnification fields. Positive cells were
counted and expressed as a percentage of total nucleated
cells. The percentage of CD68 positive macrophages that
were also positively stained for other proteins of interest
was counted by comparing serial sections or after dual-
immunohistochemistry if the antibodies were suitable, by
independent observers (JLJ, NPJ, VWPS) and the results
averaged, as described previously [24].
For dual fluorescence, primary antibodies from different
species were used and incubated together. Subsequently,
species-specific fluorophore conjugated secondary antibodies
were used to yield either a red fluorescent product at the site
of the antigen (AlexaFluor 594) or a green fluorescent product
at the site of the antigen (AlexaFluor 488). Sections were
then mounted in ProLong Gold Antifade Reagent with 4󸀠,6-
diamidino-2-phenylindole (Life Technologies, Paisley, UK;
P-36931) to fluorescently label nuclei blue. The specificity
of the immunolabeling was demonstrated by inclusion of a
negative control using isotype-specific nonimmune serum or
IgG. Images were acquired from a fluorescence microscope
using ImageProPlus image analysis software (Media Cyber-
netics) and merged if required before further analysis. The
percentage of MMP-14 positive macrophages that stained for
other proteins was counted within each lesion and expressed
as percentage of total MMP-14 positive macrophages.
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Table 1: Antibodies used for immunohistochemistry.
Antibody Supplier Cat. no. Species Dilution (Western) Dilution (IHC) Secondary antibody
Arginase-1 Santa Cruz sc-20150 Rabbit n/a 1/50 Goat anti-rabbit
CD206 R&D AF2534 Goat 1/100 1/50 Chicken anti-goat
CD68 Dako M0876 Mouse n/a 1/100 Chicken anti-mouse
COX-2 Abcam AB15191 Rabbit 1/2000 1/200 Goat anti-rabbit
MMP-14 Millipore MAB3317 Mouse 1/1000 1/200 Chicken anti-mouse
NF-kB (p65) Abcam AB7970 Rabbit 1/500 1/50 Goat anti-rabbit
TIMP-3 Millipore MAB3318 Mouse 1/1000 1/200 Chicken anti-mouse
2.3. Studies with Isolated PrimaryHumanMacrophages. Peri-
pheral blood mononuclear cells were isolated by differential
centrifugation from whole blood of healthy donors, which
were collected under South West 4 Research Ethics Com-
mittee reference 09/H0107/22. Blood (24mL per donor) was
diluted with Dulbecco’s Phosphate Buffered Saline (PBS)
without calcium and magnesium (Lonza) 1x (ratio 1 : 1).
The diluted samples were subjected to density gradient
separation on Ficoll Paque Plus (ratio 1 : 1) (GE Healthcare
Life Sciences, Buckinghamshire, UK) and centrifuged. After
centrifugation the PBMC layer was collected and washed
in Hank’s Balanced Salt Sodium (HBSS) with phenol red
without calcium and magnesium (Lonza). Monocytes were
isolated by adhering the peripheral blood mononuclear cells
to tissue culture plastic for 2 hours at a concentration of
2.5 × 10
6 cells/mL. Monocytes were cultured in RPMI media
with 2mM L-glutamine, 100 IU/mL penicillin, 100 𝜇g/mL
streptomycin, 10% fetal bovine serum (FBS; Lonza, Sigma),
and 20 ng/mL recombinant human macrophage-colony-
stimulating factor (R & D systems). The medium included
85 𝜇g/mL of fully oxidised low-density lipoprotein, oxLDL
(Intracel) from day 5 when foam-cell macrophages (FCM)
were generated. At Day 7, the medium was removed and
replaced with RPMI media supplemented with 5% FCS.
Recombinant human interferon-𝛾 (10 ng/mL R & D systems)
and lipopolysaccharide-LPS (200 ng/mL, Escherichia coli
026:B6, Sigma-Aldrich) were added for 24 hours to generate
classically activated macrophages (M1) [25] or recombinant
human interleukin-4 (20 ng/mL R & D systems) to obtain
alternatively activated macrophages (M2) [26].
2.4. Reverse Transcription-Polymerase Chain Reaction (RT-
PCR). RNA samples frommacrophages were collected using
RLT solution (Qiagen) with 𝛽-mercaptoethanol (𝛽-ME;
1 : 100 dilution). Total RNA was extracted using RNeasy Mini
kit (Qiagen) according to the manufacturer’s instructions.
RNA was quantified using a Nanodrop Spectrophotometer
and cDNA generated using a QuantiTect Reverse Transcrip-
tion Kit (100–200 ng RNA per reaction Qiagen). Real-time
quantitative PCR was performed in a Roche Light Cycler 1.5
to quantify the steady-state concentration of RNA using a
QuantiTect SYBR Green PCR Kit and primers as detailed in
Table 2. The reaction contained 3.6–7.3 ng RNA and 0.5𝜇M
primers. Denaturation for 15min at 95∘C was followed by 60
cycles of denaturation (15 seconds at 95∘C), annealing for 20
seconds, and extension for 25 seconds at 72∘C. Copy numbers
of mRNA were calculated using standard curves constructed
using the respective PCR products eluted from agarose gels.
All fragments were sequenced to confirm identity (Cogenics,
Takeley, UK). Primers used and their annealing temperatures
are in Table 2.
2.5. Western Blotting. Adherent cells were washed with PBS
on ice and then lysed with ice-cold 1% SDS lysis buffer. The
Bicinchoninic acid (BCA) Kit (Pierce) was used to estimate
protein concentration (all in duplicate) of cell lysates accord-
ing to kit protocol. Protein concentration was read at 560 nm
on a Multiskan Ascent (Thermo Electron Corporation) plate
reader. NuPAGENovex Bis-TrisMini Gel system (Invitrogen,
Life Technologies, Paisley, UK) was used for western blot
experiments. 10 𝜇g of total protein was loaded on 4–12%
Bis-Tris-HCl buffered (pH 6.4) polyacrylamide precast gels
(Invitrogen, Life Technologies, Paisley, UK) and run in
MES-SDS Running Buffer 1x (Invitrogen, Life Technologies,
Paisley, UK) according to manufacturer instructions. After
electrophoresis, gels were transferred to a 0.45 𝜇m nitrocel-
lulose membrane in NOVEX NuPAGE Transfer Buffer 1x
plus 5% Methanol (v/v). Following transfer, the nitrocellu-
lose membrane was blocked in 5% milk solution in Tris
buffered solution containing Tween (TBS-T) (200mM Tris,
2% Tween 20, pH 7.6). The membrane was then incubated
over night at 4∘C using the antibodies described in Table 1
diluted in 2mL of SignalBoost Solution 1 (Calbiochem-
Novabiochem Ltd., Nottingham, UK). The following day the
membrane was incubated with 5% milk solution in TBS-T
and then with the applicable horseradish peroxidase (HPR)-
labelled secondary antibody (Dako, Dorset, UK) diluted
1 : 1000 in SignalBoost Solution 2 (Calbiochem-Novabiochem
Ltd., Nottingham, UK). After incubation the membrane was
washed in TBS-T. To detect the peroxidise labelled proteins,
an enhanced chemiluminescence (ECL) detection system
(GE Healthcare Life Sciences, Buckinghamshire, UK) was
used. The membrane was incubated with ECL reagent mix
(solution A and solution B at a ratio of 1 : 1) and exposed to
X-ray film for the desired length of time. As a loading control
0.5 𝜇g/mL of either anti-𝛽-actin antibody (A2228, Sigma)
or anti-GAPDH antibody (MAB374, Millipore) was used.
Detected bands were quantified using a Bio-Rad GS-690
scanning densitometer (Bio-Rad, Hemel Hempstead, UK)
and were normalised by relevant 𝛽-actin or GAPDH values.
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Table 2: Primers for quantitative RT-PCR.
Primer Sequence Annealing temp. (∘C) Fragment size (bp)
MMP-14 Forward GGAGACAAGCATTGGGTGTT 60 343
Reverse GGTAGCCCGGTTCTACCTTC
TIMP-3 Forward CTTCCGAGAGTCTCTGTGGCCTTA 60 230
Reverse CTCGTTCTTGGAAGTCACAAAGCA
COX-2 Forward GCCATGGGGTGGACTTAAATCATA 60 168
Reverse CAGGGACTTGAGGAGGGTAGATCA
CD206 Forward CGGTGACCTCACAAGTATCCACAC 58 216
Reverse TTCATCACCACACAATCCTCCTGT
IkB𝛼 Forward CTACTGGACGACCGCCACGACAGC 60 58
Reverse CGAGGCGGATCTCCTGCAGCTCCTTG
36B4 Forward GCCAGCGAAGCCACGCTGCTGAAC 60 76
Reverse CGAACACCTGCTGGATGACCAGCCC
2.6. Statistical Methods. For histomorphometry, differences
between categorical and continuous variables were analysed
by using an independent Student’s 𝑡-test in case of normally
distributed data, and a Mann-Whitney 𝑈 test in case of not
normally distributed data. Differences between ordinal and
continuous data were analysed by using a Kruskal-Wallis
test, in case of not normally distributed data. Differences
between dichotomous and categorical data were analysed by
using a Chi-square test. Differences between 2 continuous
variables were analysed with a Spearman correlation test
in case of not normally distributed data. In all cases 𝑃 <
0.05 was considered significant. All statistical analysis was
performed with SPSS version 17 (SPSS Inc., Chicago, IL,
USA). Quantitative RT-PCR results normalised to the values
for 18 s RNA were transformed to logarithms and analysed
by ANOVA followed by Student’s 𝑡-test with Bonferroni
correction.
3. Results
3.1. MMP-14 and TIMP-3 mRNA Expression in Human Pri-
mary Macrophages and FCMs In Vitro. Human monocyte-
derivedmacrophages were differentiated withM-CSF (MMs)
and some from each batch were treated with oxidised LDL
to generate foam-cell macrophages (FCMs), as previously
validated in our laboratory [27]. Conversion of MMs to
FCMs did not affect mRNA expression of MMP-14 or TIMP-
3 (Figure 1(a)) or COX-2 and I𝜅B𝛼, markers of proinflamma-
tory activation, or CD206, a gene that is present constitutively
but upregulated by anti-inflammatory activation [12, 13]
(Figure 1(a)). Proinflammatory activation with LPS and IFN𝛾
(referred to as M1 conditions [26]) significantly increased
expression of MMP-14 by 4.5- and 7.3-fold, I𝜅B𝛼 mRNA (a
surrogate marker of NF𝜅B signalling [28]) by 7.5- and 6.7-
fold, andCOX-2mRNAby 146- and 187-fold, inmacrophages
(MM1) and FCMs (FCM1), respectively (Figure 1(a)). By
contrast, proinflammatory activation decreasedmRNA levels
of TIMP-3 by 74% and 89% and CD206 by 81% and 86%
in macrophages or FCMs, respectively (Figure 1(a)). Anti-
inflammatory activation with IL-4 (referred to as M2 condi-
tions [26]) had no effect on MMP-14, COX-2 or I𝜅B𝛼mRNA
levels but significantly increased TIMP-3 mRNA expression
by 1.9- and 2.6-fold and CD206 expression by 7.5- and
9.9-fold in MMs (MM2) and FCMs (FCM2), respectively
(Figure 1(a)).
3.2. MMP-14 and TIMP-3 Protein Expression in Macrophages
and FCMs In Vitro. Consistent with the mRNA data,
proinflammatory activation significantly elevated protein
levels of MMP-14 and COX-2 and significantly decreased
those of TIMP-3 and CD206 in nonfoamy macrophages
(Figures 1(b) and 1(c)). Anti-inflammatory activation (MM2)
also increased macrophage TIMP-3 and CD206 protein
levels (Figures 1(b) and 1(d)), consistent with the mRNA
data. We conclude that proinflammatory macrophages
are MMP-14hi TIMP-3lo whereas unactivated and anti-
inflammatory stimulated macrophages are comparatively
MMP-14lo TIMP-3hi. Foam-cell formation significantly
increased protein expression of MMP-14 and decreased
TIMP-3 levels (Figures 1(e) and 1(f)), despite not changing
the mRNA levels, in agreement with our previous findings
in during rabbit macrophage foam-cell formation [7]. These
results could be explained by the additional involvement
of a posttranscriptional mechanism, such as regulation
by microRNA (miR). Indeed, we recently showed that
high levels of miR-24 in nonfoamy macrophages limit
macrophage MMP-14 protein expression [29]. We observed
a 70% decrease in miR-24 levels in FCMs compared to MMs
(Figure 1(g)), consistent with the increased MMP-14 protein
levels. Interestingly, in contrast to mRNA expression, pro- or
anti-inflammatory activation of FCMs did not affectMMP-14
protein expression (Figure 1(h)), which suggests that the
effect of the miR is dominant. Pro- or anti-inflammatory
activation of FCMs did not affect TIMP-3 protein expression
either when compared to nonactivated FCMs (Figure 1(i)).
TIMP-3 protein expression may also be subject to miR
regulation but this has not yet been demonstrated in
macrophages. In summary, our results imply that nonfoamy
macrophages are MMP-14hi TIMP-3lo when classically
activated whereas FCMs are MMP-14hi TIMP-3lo at the
protein level irrespective of their activation status.
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Figure 1: Continued.
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Figure 1: (a) mRNA expression of M-CSF differentiated macrophages (MM) and foam-cell macrophages (FCM) after activation with IFN𝛾
and LPS (MM1 and FCM1) or IL-4 (MM2 and FCM2). Data are mean ± SEM; 𝑛 = 7; ∗ = 𝑃 < 0.05 compared to MM and MM2; # =
𝑃 < 0.05 compared to FCM and FCM2; $ = 𝑃 < 0.05 compared to MM and MM1; and ‡ = 𝑃 < 0.05 compared to FCM and FCM1.
((b)–(d)) Densitometric quantification and representative Western blots for MMP-14, COX-2, TIMP-3, and CD206 in M-CSF differentiated
macrophages (MM) or after activation with IFN𝛾 and LPS (MM1) or IL-4 (MM2). Data are mean± SEM, ∗𝑃 < 0.05 compared to MM, 𝑛 = 8.
((e)-(f)) Densitometric quantification and representativeWestern blots forMMP-14 (e) and TIMP-3 (f) inM-CSF differentiatedmacrophages
(MM) and foam-cell macrophages (FCM). Data are mean ± SEM, ∗𝑃 < 0.05 compared to MM, ∗𝑃 < 0.001 compared to MM, 𝑛 = 4.
(g) QPCR expression of miR-24 in M-CSF differentiated macrophages (MM) and foam-cell macrophages (FCM). Data are mean ± SEM,
∗
𝑃 < 0.05 compared to MM. ((h)-(i)) Densitometric quantification and representative Western blots for MMP-14 (h) and TIMP-3 (i) in
foam-cell macrophages (FCM) after activation with IFN𝛾 and LPS (FCM1) or IL-4 (FCM2). Data are mean ± SEM; 𝑛 = 4.
3.3. Localisation of MMP-14 and TIMP-3 in Human Carotid
Atherosclerotic Plaques. Macrophages and FCMs were iden-
tified in plaques using immunohistochemistry for CD68.
The CD68 positive cells varied widely in morphology from
large, highly foamy cells to those with very few or no
lipid inclusions. We counted all cells irrespective of mor-
phology. MMP-14 positive macrophages/FCMs were found
predominantly in the shoulder regions (SR) of atheromatous
carotid plaques (Figures 2(a)–2(c)), whereas TIMP-3 posi-
tive macrophages/FCMs occurred predominantly within and
around the fibrous cap (FC) of fibrous atheromatous plaques
(Figures 2(d)-2(e)). The specificity of the antibodies used is
demonstrated in Figure 2. In line with our previous findings
[7], regions of plaques tended to be either MMP-14 positive
and TIMP-3 negative (Figure 2(g) compared to Figure 2(h))
or MMP-14 negative and TIMP-3 positive (Figure 2(i)
compared to Figure 2(j)). Dual Immunohistochemistry (as
described previously [24]) revealed that in plaque regions
with abundant CD68 positive FCMs, MMP-14 colocalised
with nuclear-localised NF-𝜅B p65 subunit, a recognised
marker of proinflammatory activation. When counted,
approximately 80% of MMP-14 positive FCMs also had
nuclear-localised NF𝜅B (Figures 3(a)–3(d)), which implies
that proinflammatory activation associated with MMP-14
upregulation in macrophages/FCMs in plaques. To gain
further insight, we employed arginase-1, which is a marker
for anti-inflammatorymousemacrophages [30] and is down-
regulated in a subpopulation of human FCMs in advanced
plaques [31]. Arginase-1 and MMP-14 were coexpressed
in more than 50% of intraplaque macrophages/FCMs and
the number of arginase-1 and MMP-14 positive macrophages
was correlated in advanced plaques (𝑟2 = 0.960; 𝑃 < 0.0001,
Figure 4). These results are consistent with our in vitro data
showing high MMP-14 protein levels in FCMs irrespective
of M1/M2 activation state (Figure 4). Conversely to MMP-
14, less than 1% of TIMP-3 positive macrophages/FCMs
demonstrated nuclear-localisedNF-𝜅Bp65 (Figure 5), imply-
ing that few were classically activated. Approximately 80% of
macrophages/FCMs that were TIMP-3 positive also stained
for CD206, which we showed to be expressed in unacti-
vated (MM) and alternatively activated (MM2) macrophages
(Figures 3(f)–3(i)). We therefore concluded that CD206 and
TIMP-3 positive macrophages/FCMs in plaques could be
unactivated or IL-4 activated.
3.4. Relationship of MMP-14 and TIMP-3 Staining to Histo-
logical Features of Plaque Stability and Occurrence of Symp-
toms in Carotid Atherosclerotic Plaques. We next investigated
the association between MMP-14 and TIMP-3 staining and
plaque composition. Carotid plaques entered into AtheroEx-
press are given an initial classification into atheromatous,
fibrous-atheromatous, or fibrous plaques based on a large
lipid core, high abundance of macrophages, and low abun-
dance of smooth muscle cells (SMCs) and collagen content
[20, 21, 32] (Table 3). Of note, male and older patients are
overrepresented in the group with atheromatous plaques
(Table 4). By comparison with these previous assignments
we found that the percentage of MMP-14 (Figure 6(a)) and
COX-2 (Figure 6(b)) positive macrophages/FCMs was sig-
nificantly greater in atheromatous or fibrous-atheromatous
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Figure 2: ((a)–(f)) Immunolocalisation of macrophages (CD68), MMP-14, and TIMP-3 in human atheromatous ((a)–(c)) and fibrous-
atheromatous ((d)-(e)) carotid plaques. Panels (b)-(c) and (e)-(f) are higher magnification fields of boxes depicted in panels (a) and
(d), respectively. SR denotes shoulder region, NC denotes necrotic core, and FC denotes fibrous cap. ((g)–(j)) Immunohistochemistry of
atheromatous carotid plaques demonstrating MMP-14hi TIMP-3lo ((g) and (h), serial sections) and MMP-14lo TIMP-3hi ((i) and (j), serial
sections) foam-cell macrophage regions. Arrows indicate same cells in adjoining serial sections. ((k)–(t)) Immunohistochemical staining
(brown product colour) of carotid plaque sections for (k) MMP-14, (l) COX-2, (m) NF𝜅B, (n) TIMP-3, and (o) CD206 and their relevant
control IgG on serial sections ((p)–(t), resp.).
compared to fibrous plaques. By contrast, the percent-
age TIMP-3 (Figure 6(a)) and CD206 (Figure 6(b)) pos-
itive macrophages/FCMs increased in fibrous compared
to fibrous-atheromatous and atheromatous carotid plaques.
Despite the small number of asymptomatic patients in our
cohort, significantly higher MMP-14 positivity was found
in plaques from symptomatic compared to asymptomatic
patients (Figure 6(c)). There was also a trend towards lower
TIMP-3 positivity in plaques from symptomatic patients
(Figure 6(c)).
Amplifying the relationships to overall plaque designa-
tion, we found a higher percentage of MMP-14 positive
macrophages/FCMs was associated with plaques showing
high lipid and macrophage content or decreased SMC
number, which are related to plaque instability, whereas
the converse was observed for TIMP-3 positive FCMs
(Figure 7). TIMP-3 positive macrophages/FCMs were also
significantly associated with increased collagen content
and reduced plaque neovascularisation (Figure 7), other
markers of plaque stability. Furthermore, the percentage
of MMP-14 positive macrophages/FCMs across all the
sections correlated strongly with total macrophage num-
ber and negatively with SMC number (Table 5). Percent-
age positivity for MMP-14 and COX-2 also correlated
with each other (Table 5). Conversely, the percentage of
TIMP-3 positive macrophages/FCMs strongly correlated
negatively with macrophage number and positively with
SMC number (Table 5). Positivity for TIMP-3 correlated
directly with CD206 and inversely with MMP-14 (Table 5).
Other characteristics including the presence of calcification,
intraplaque haemorrhage, and thrombus formation were also
recorded. Positivity of MMP-14 or TIMP-3 was unrelated
to plaque calcification (data not shown). However, plaques
with intraplaque haemorrhage had a significantly higher
percentage of MMP-14 positive macrophages/FCMs and
tended to have a lower percentage of TIMP-3 positive FCMs
(Table 6).
4. Discussion
Our main new findings are that macrophages activated
with proinflammatory stimuli or foam-cell macrophages
(FCMs) irrespective of inflammatory activation are MMP-
14
hi TIMP-3lo compared to unstimulated (M-CSF differen-
tiated; MM) or anti-inflammatory (IL-4 activated; MM2)
macrophages. Furthermore, MMP-14 positive FCMs are
more abundant and TIMP-3 positive FCMs are less abundant
in plaques with vulnerable rather than stable characteristics.
Multiple macrophage and FCM phenotypes have been
previously described [33, 34]. Classical macrophage acti-
vation in vitro with proinflammatory stimuli is charac-
terised by NF-𝜅B-dependent upregulation of a variety of
additional proinflammatory mediators and enzyme systems,
including COX-2. By contrast, in vitro activation with anti-
inflammatory stimuli such as IL-4 or IL-13mediates a distinct
transcriptomic response dependent on STAT-6 phosphory-
lation [26, 33]. Our results demonstrate a prominent effect
of classical activation on MMP-14 mRNA expression in
macrophages and FCM [35], consistent with previous work
on human monocytes [36] and macrophages [35] demon-
strating that NF-𝜅B activation facilitatesMMP-14 expression.
Formation of foam cells per se did not lead to pro- or anti-
inflammatory macrophage activation (Figure 1), consistent
with previous studies [16, 37]. However, transformation to
FCM increased MMP-14 protein expression, regardless of
proinflammatory activation. FCMs appear resistant to M1
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Figure 3: (a)–(j) Representative images of immunohistochemical labelling of unstable ((a)–(e)) and stable ((f)–(j)) human carotid artery
atherosclerotic plaques, for macrophages (CD68, panels (a) and (f)), and colocalisation of nuclear-localised NF𝜅B with MMP-14 ((b)–(d)),
and CD206 with TIMP-3 ((h)–(j)), with nuclei counterstained with DAPI (blue). Box in panels (a) and (f) represents higher magnification
in panels (b)–(e) and (g)–(j), respectively. Scale bar in (a) represents 250𝜇m and is applicable to panels (a) and (f), whereas scale bar in (b)
represents 100 𝜇m and is applicable to panels (b)–(e) and (g)–(j). Arrows in panels (b)–(d) indicate MMP-14 +ve FCMs with nuclear NF𝜅B.
Panels (e) and (j) represent negative controls where the primary antibodies were replaced with the relevant species IgG. (k)The percentage of
MMP-14 positive FCMs that also stained for nuclear-localised NF𝜅B was significantly greater (∗∗∗𝑃 < 0.001) compared to only cytoplasmic
NF𝜅B or no staining. (l) The percentage of TIMP-3 positive FCMs that stained also for CD206 was significantly greater (∗∗∗𝑃 < 0.001)
compared to those stained for TIMP-3 or CD206 alone.
Table 3: Atherosclerotic plaque characteristics.
Plaque characteristics Plaque phenotype Gradation 𝑃 value
% fat/atheroma
No/<40%/>40%
Fibrous 15 (50%) 15 (50%) 0 (0%)
0.0001Fibrous-atheromatous 0 (0%) 11 (92%) 1 (8%)
Atheromatous 0 (0%) 2 (5%) 35 (95%)
Collagen semiquantitative
(minor/moderate/heavy)
Fibrous 1 (4%) 14 (45%) 15 (52%)
0.0001Fibrous-atheromatous 2 (17%) 7 (58%) 3 (25%)
Atheromatous 17 (46%) 19 (51%) 1 (3%)
SMC semiquantitative
(no/minor/moderate/heavy)
Fibrous 0 (0%) 0 (0%) 10 (33%) 20 (67%)
0.0001Fibrous-atheromatous 0 (0%) 3 (25%) 7 (58%) 2 (17%)
Atheromatous 2 (5%) 30 (81%) 5 (14%) 0 (0%)
SMC quantitative
% plaque area median [IQR]
Fibrous 4.31 [1.73–5.69]
0.0001Fibrous-atheromatous 1.31 [0.39–4.62]
Atheromatous 0.53 [0.31–1.07]
Macrophage
semiquantitative
(no/minor/moderate/heavy)
Fibrous 7 (23%) 20 (67%) 3 (10%) 0 (0%)
0.0001Fibrous-atheromatous 3 (25%) 6 (50%) 2 (17%) 1 (8%)
Atheromatous 0 (0%) 0 (0%) 19 (51%) 18 (49%)
Macrophage quantitative
% plaque area median [IQR]
Fibrous 0.20 [0.05–0.63]
0.0001Fibrous-atheromatous 0.15 [0.06–0.50]
Atheromatous 1.13 [0.60–2.52]
Thrombus present
(no/minor/moderate/heavy)
Fibrous 13 (43%) 14 (47%) 2 (7%) 1 (3%)
0.0001Fibrous-atheromatous 2 (17%) 7 (58%) 1 (8%) 2 (17%)
Atheromatous 4 (11%) 10 (27%) 16 (43%) 7 (19%)
CD34 staining
Number of vessels median
[IQR]
Fibrous 6.7 [3.8–9.5]
0.5000Fibrous-atheromatous 6.5 [3.8–10.4]
Atheromatous 7.0 [4.3–11.0]
𝑃 values for differences among the three groups of semiquantitative histological markers and percentage of macrophages and smooth muscle cells were
determined using the Kruskal-Wallis test.
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Figure 4: ((a)–(d)) Representative images of immunohistochemical labelling of advanced human carotid artery atherosclerotic plaques, for
colocalisation of MMP-14 (a) with arginase-1 (b), with nuclei counterstained with DAPI (blue; (c)). Scale bar in (a) represents 100 𝜇m and is
applicable to panels (a)–(d). (e)The percentage of MMP-14 positive FCMs that also stained for arginase-1 was significantly greater compared
to only MMP-14 or arginase-1 (∗𝑃 < 0.05; 𝑛 = 10 per group; data expressed as mean ± SEM). (f) Correlation of arginase-1 and MMP-14
positive macrophages in human carotid artery atherosclerotic plaques (𝑟2 = 0.960; 𝑃 < 0.0001; 𝑛 = 10).
and M2 cytokine-stimulation but employ a posttranscrip-
tional pathway to modulate MMP-14 protein expression and
subsequent activity. Indeed we have recently identified the
involvement of a microRNA, miR-24, in the direct regulation
of macrophage MMP-14 protein expression [29]. Further
evidence for a novel pathway in regulating FCM MMP-
14 protein expression is provided by our demonstration
that MMP-14 positive macrophages/FCMs in plaques corre-
lated with classical activation markers, COX-2 and nuclear-
localised NF-𝜅B, and with the well-recognised marker of
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Figure 5: Immunohistochemical staining of carotid plaque sections for (a) 4󸀠,6-diamidino-2-phenylindole (DAPI), (b) NF𝜅B, (c) TIMP-
3, and (d) merged, demonstrating that the percentage of TIMP-3 positive FCMs with no nuclear NF𝜅B was significantly greater (𝑛 = 20,
∗
𝑃 < 0.0001) compared to cytoplasmic or nuclear NF𝜅B staining, as depicted in adjoining graph (e).
alternative activation, arginase-1. Hence foam-cell formation
rather than M1 or M2 macrophage polarisation appears
responsible for the MMP-14hi FCMs detected in advanced
human atherosclerotic plaques.
By contrast to MMP-14, TIMP-3 mRNA was decreased
during proinflammatory activation of macrophages or dur-
ing foam-cell formation. A combination of these factors
probably accounts for the TIMP-3lo populations seen in
plaques. TIMP-3 positive macrophages/FCMs correlated and
colocalised with the mannose receptor (MR), CD206. In
agreement with other previous studies [38], we found that
CD206 and TIMP-3 were highly expressed in macrophages
differentiated in M-CSF (MM) and upregulated by IL-4
(MM2). However, TIMP-3 expression was only doubled
after IL-4 treatment (Figure 1) and is therefore present in
both phenotypes. MR positive macrophages/FCMs were
previously reported to be mainly located away from the
lipid core of plaques [12, 13], consistent with the location of
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Figure 6: Relationship betweenMMP-14 and TIMP-3 staining and plaquemorphology or symptoms.The percentage of CD68 positive FCMs
that stained also for (a) MMP-14 and TIMP-3, or (b) COX-2 and CD206, was related to atheromatous, fibrous-atheromatous and fibrous
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Data analyzed using a Kruskal-Wallis test (∗𝑃 < 0.05, ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.001). Patient numbers within each group are depicted below each
bar graph.
TIMP-3 positive macrophages/FCMs in our study. Although
little is known about the regulation of TIMP-3 transcrip-
tion [39], the striking decrease in protein expression we
observed upon foam-cell formation is consistent with pre-
vious observations that posttranscriptional mechanisms can
regulate TIMP expression during macrophage development
[40]. Studies beyond the present scope are going on in our
laboratories to investigate this possibility.
Injurious roles for MMP-14 and protective effects of
TIMP-3 have been suggested from animal studies (see the
Introduction). Consistent with these proposals, we found that
MMP-14 positive FCM subpopulations were associated with
histological features of plaque vulnerability in carotid plaques
based primarily on correlating quantitative plaque character-
istics derived from all the sections irrespective of histological
appearance (Table 4).The conclusions were also confirmed in
carotid atherosclerotic plaques by prior blinded assignment
of lesions based on overall histological appearance (Figures
6 and 7). This second analysis can be criticised because it
is based on subjective visual observation, although we have
shown previously that there is good intraobserver agreement
[23]. It is also evident that there is a gender imbalance
between the differing plaque phenotypes which may act as
a source of variability in the statistical analysis. Nonetheless,
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Figure 7: The percentage of MMP-14 and TIMP-3 positive foam-cell macrophages (median [95% confidence limits]) was compared with
semiquantitative plaque features and 𝑃 values computed with a Kruskal-Wallis test (∗𝑃 < 0.05, ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.001).
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Table 4: Patient characteristics.
Patient characteristics Fibrous plaques(𝑛 = 30)
Fibrous-atheromatous
(𝑛 = 12)
Atheromatous plaques
(𝑛 = 37) 𝑃 value
Symptomatic patients 𝑛 (%) 22 (73%) 11 (92%) 36 (97%) 0.012∗
Amaurosis fugax 𝑛 (%) 6 (20%) 5 (42%) 1 (3%)
0.010∗TIA 𝑛 (%) 12 (40%) 4 (33%) 25 (68%)
Stroke 𝑛 (%) 4 (13%) 2 (17%) 10 (27%)
Asymptomatic 𝑛 (%) 8 (27%) 1 (8%) 1 (3%)
M (D)/F (C) 11D 19C 11D 1C 34D 3C 0.007∗
Age mean (sd) 65 (9.6) 73 (8.1) 70 (7.7) 0.016∗
Hypertension 𝑛 (%) 22 (73%) 10 (83%) 31 (84%) 0.540
Smoking 𝑛 (%) 9 (30%) 5 (42%) 13 (35%) 0.761
Diabetes 𝑛 (%) 5 (17%) 0 (0%) 4 (11%) 0.304
Hypercholesterolemia 𝑛 (%) 17 (57%) 6 (50%) 20 (54%) 0.924
Positive family history of heart disease 7 (23%) 2 (17%) 10 (27%) 0.761
History of coronary intervention 𝑛 (%) 7 (23%) 3 (25%) 8 (22%) 0.967
History of peripheral intervention 𝑛 (%) 6 (20%) 1 (8%) 10 (27%) 0.379
History of myocardial infarction 4 (13%) 3 (25%) 1 (3%) 0.064
Statins 16 (53%) 5 (42%) 26 (70%) 0.147
Oral anticoagulants 6 (20%) 4 (33%) 3 (8%) 0.098
Aspirin 18 (60%) 3 (25%) 17 (46%) 0.114
Carbasalate calcium 8 (27%) 8 (67%) 20 (54%) 0.023∗
Aspirin or Carbasalate calcium 24 (80%) 9 (75%) 34 (92%) 0.237
Dipyridamole 18 (60%) 4 (33%) 22 (60%) 0.238
Clopidogrel 3 (10%) 0 (0%) 7 (19%) 0.198
Diuretics 9 (30%) 2 (17%) 11 (30%) 0.881
Beta blockers 13 (43%) 3 (25%) 18 (49%) 0.355
Calcium antagonists 6 (20%) 3 (25%) 12 (32%) 0.514
ACE inhibitors 11 (37%) 3 (25%) 12 (33%) 0.764
Angiotensin II inhibitors 5 (17%) 2 (17%) 4 (11%) 0.755
Insulin 2 (7%) 0 (0%) 0 (0%) 0.187
Oral glucose inhibitors 3 (10%) 0 (0%) 4 (11%) 1.000
∗
𝑃 < 0.05.
Table 5: Correlations of immunostains with histological parameters for plaque vulnerability in human carotid plaques.
Plaque characteristic % of MMP-14
hi FCMs % of TIMP-3hi FCMs
𝑛 rho 𝑃 value 𝑛 rho 𝑃 value
Macrophage density 79 0.453 <0.001 68 −0.316 0.009
SMC density 76 −0.466 <0.001 66 0.283 0.021
% of MMP-14hi FCMs x x x 71 −0.366 0.002
% of COX-2+ FCMs 32 0.726 <0.001 28 −0.185 0.345
% of CD206+ FCMs 27 −0.013 0.948 27 0.606 0.001
Correlations are shown between the percentage of CD68 positive foam-cell macrophages (FCMs) also positive for MMP-14 and TIMP-3 with quantitative
histological markers and percentage of CD68 positive for COX-2 and CD206 using Spearman correlation tests. Negative correlations are shown in italics.
collectively our results demonstrate that MMP-14 positive
FCMs associate with plaque vulnerability. Whereas TIMP-3
positive macrophages correlate with plaque stability.
In summary our findings show that FCMs in vulner-
able atherosclerotic plaques can exhibit increased MMP-
14 and decreased TIMP-3 protein expression. This leads to
heightened invasive capability, increased proliferation, and
augmented susceptibility to apoptosis, as we have previously
demonstrated [7]. Our work therefore suggests that reducing
MMP-14 activity and increasing that of TIMP-3 could be
valid therapeutic approaches to reduce plaque rupture and
myocardial infarction.
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Table 6: MMP-14 and TIMP-3 expression and plaque characteristics.
Plaque feature Absent 𝑛 Present 𝑛 𝑃 value
MMP-14 (% of positive foam cell macrophages)
Intraplaque haemorrhage 24 [0–64] 51 67 [28–81] 28 0.007
Any thrombus or haemorrhage 11 [1–48] 24 59 [6–81] 55 0.026
TIMP-3 (% of positive foam cell macrophages)
Intraplaque haemorrhage 24 [8–43] 44 11 [5–25] 24 0.095
Any thrombus or haemorrhage 28 [8–77] 22 13 [5–34] 46 0.067
The percentage ofMMP-14 and TIMP-3 positive foam cell macrophages (median [95% confidence limits]) was compared with semiquantitative plaque features
and P values computed with a Kruskal-Wallis test.
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